Formulation and Evaluation of Magnetic Microspheres of Cytarabine Magnetic microspheres of Cytrarabine
Iranian Journal of Pharmaceutical Sciences,
Vol. 15 No. 4 (2019),
1 Mehr 2019
,
Page 31-40
https://doi.org/10.22037/ijps.v15.40452
Abstract
Cytarabine is the drug of choice for treatment of leukemia. However, many formulations have been prepared, due to certain limitations they could not prove to be effective ones, therefore magnetic microspheres are formulated as they minimise the Reticuloendothelial clearance and target site specificity can be increased. The current study aimed to utilize nanotechnology to develop magnetic microspheres. Magnetic microspheres of Cytarabine were prepared using two polymers are chitosan and sodium alginate by the continuous solvent evaporation method. Optimization was done and nine different formulations were prepared. Particle sizes, encapsulation efficiency, magnetic responsiveness, in vitro release of all the formulations were determined. The studies demonstrated that F7 was the best formulation and drug can thus be reached the targeted site as magnetic responsiveness was also good. Novel magnetic microspheres were developed with less Reticuloendothelial clearance and target site specificity; however, further clinical investigations are necessary to evaluate its therapeutic effectiveness.
- Magnetic
- microspheres
- Cytarabine
- Reticuloendothelial
- target
- specificity
How to Cite
References
[2] Nikalje AP. Nanotechnology and its Applications in Medicine. Med. chem. (2015) 5: 081-089.
[3]Vinod KR, Reddy R, Banji D, Reddy V, Sandhya S. Critical review on mucoadhesive drug delivery systems. Hygeia J. D. Med. (2012) 6 (1): 7-12.
[4] Hee Jae yoon, Woo Dong Jang. Polymeric supramolecular systems for drug delivery. JMC.(2010) 2: 211-222.
[5] A-J, Ohlendorf D., Huhnt, W., Huhn, D. Clinical experiences with magnetic drug targeting: A Phase I study with 4'-Epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. (1996) 56 (20):
4686–4693.
[6] Khar RK, Diwan M. Advances in Novel and Controlled Drug Delivery, New Delhi, CBS Publishers And Distributors (2001): 452-462.
[7]Alexiou C, Arnold W, Hulin P,Klein RJ, Renz H, Parak FG. Magnetic mitoxantrone nanoparticles detection by histology, X Ray and MRI after magnetic tumour targeting. J Magn. Magn. Mater (2001)225(1-2):187-193.
[8]Jain NK. Controlled and Novel Drug Delivery, New Delhi, CBS Publishers and Distibutors (2002)1:14.
[9]Kakar Satinder, Singh Ramandeep, Batra Deepa. Preparation and evaluation of magnetic microspheres of 5-aminosalicyclic acid. J. Acute Dis. (2013) 2 (3):226-231.
[10]Winter JN, Variakojis, D, Gaynor ER. Low-dose cytosine arabinoside (Ara-C) therapy in myelodysplastic syndromes and acute leukemia. J.Cancer. (1985) 56: 443- 449.
[11]Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J. Liposome. Res. (1994) 4: 667-687.
[12]Yuan F, Lwunig, M, Huang SK, Berk DA,Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. (1994) 54: 3352-3356.
- Abstract Viewed: 367 times
- IJPS_Volume 15_Issue 4_Pages 31-40 Downloaded: 315 times